Immune‑based therapies are rapidly reshaping follicular lymphoma care, with multiple chemotherapy‑free options—like tafasitamab‑based and epcoritamab‑based combinations—now available for relapsed ...

Circulating tumor DNA predicts recurrence and splits disease into two subgroups of Hodgkin lymphoma. New drug targets or changes in treatments may reduce toxicity. A Stanford Medicine-led, ...

These results highlight the need for clinicians to investigate potential high-grade lymphoid malignancies in cases of refractory CAD.

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

Nodular sclerosis Hodgkin lymphoma frequently presents with chest or neck adenopathy and characteristic fibrous bands on histology, and remains highly curable despite advanced-stage presentations.

Being diagnosed with a serious disease like Hodgkin lymphoma is a lot to digest. But once you’ve had time to process your diagnosis, talk will likely turn to the treatments for classic Hodgkin ...

Adults who beat Hodgkin lymphoma and made it past the five-year mark still died at nearly twice the rate expected for the general US population, according to a new analysis of more than 20,000 ...

Gastric mucosa-associated lymphoid tissue lymphoma, usually shortened to gastric MALT lymphoma, is one of the more deceptive ...

Please provide your email address to receive an email when new articles are posted on . In marginal zone lymphoma, systemic treatment lowered new Sjögren’s disease activity risk, while combination ...

Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc. How one approaches patient care in lymphoma ...

Verdinexor tablets are now available for dogs with lymphoma after receiving full FDA approval earlier this year, offering an at-home treatment option that is given twice weekly and showed a longer ...